Assuming the COMPASS results are enough to convince regulators to make the low dose of rivaroxaban used in the study available to clinicians, the trial should influence how patients with stable ...

MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ — MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

COMPASS STUDY PRESENTED AT ESC CONGRESS 2017 – LARGEST RIVAROXABAN STUDY TO DATE, ENROLLED 27,395 PATIENTS TO INVESTIGATE CAD AND PAD Bayer’s data shows Xarelto® (rivaroxaban) significantly lowers the ...

COMPASS-CAD started enrolling patients in November 2024 at Penn Medicine and has expanded to other sites. In COMPASS-CAD, patients classified as intermediate or borderline risk based on traditional ...